SEOUL, Jan. 31 (Yonhap) -- Celltrion Inc., a major South Korean biopharmaceutical firm, said Friday its new biosimilar for an autoimmune disease treatment has received approval from the U.S. Food and ...
The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.
On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...
US biotech major Amgen =announced that it has reached resolution of its patent infringement litigation related to South Korea ...
As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...
An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...
Three players in the biosimilar space have already sparked hope for the new year, with each having big business or regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback